111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于多学科团队（MDT）的肝癌治疗方法：关于肿瘤委员会及其他方面的讨论文件
Received 8 September 2025
Accepted for publication 12 November 2025
Published 26 November 2025 Volume 2025:18 Pages 7739—7748
DOI https://doi.org/10.2147/JMDH.S566098
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Judith Johnson
Mengdi Qi,1 Min Qi2,3
1Department of Interventional Radiology, the First Hospital of China Medical University, Shenyang, 110000, People’s Republic of China; 2Director of the Department of Geriatrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471000, People’s Republic of China; 3Luoyang Municipal Key Laboratory of Individualized Therapy for Hepatocellular Carcinoma, Luoyang, 471000, People’s Republic of China
Correspondence: Min Qi, Luoyang Municipal Key Laboratory of Individualized Therapy for Hepatocellular Carcinoma, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471000, People’s Republic of China, Email qimin19720629@163.com
Abstract: Hepatocellular carcinoma (HCC) remains one of the most common malignancies worldwide. Its high aggressiveness and complex pathophysiology contribute to diverse but often suboptimal treatment outcomes. The Multidisciplinary Team (MDT) integrates expertise from various specialties to provide personalized and optimal treatment strategies for individual patients. However, conventional MDT face limitations related to logistics, consensus-building, and patient communication. This review aims to discuss the current status and challenges of MDT in liver cancer management and explore emerging innovative technologies that can transcend the conventional model.
Keywords: hepatocellular carcinoma, multidisciplinary tumor board, precision medicine
1Department of Interventional Radiology, the First Hospital of China Medical University, Shenyang, 110000, People’s Republic of China; 2Director of the Department of Geriatrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471000, People’s Republic of China; 3Luoyang Municipal Key Laboratory of Individualized Therapy for Hepatocellular Carcinoma, Luoyang, 471000, People’s Republic of China
Correspondence: Min Qi, Luoyang Municipal Key Laboratory of Individualized Therapy for Hepatocellular Carcinoma, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, 471000, People’s Republic of China, Email qimin19720629@163.com
Abstract: Hepatocellular carcinoma (HCC) remains one of the most common malignancies worldwide. Its high aggressiveness and complex pathophysiology contribute to diverse but often suboptimal treatment outcomes. The Multidisciplinary Team (MDT) integrates expertise from various specialties to provide personalized and optimal treatment strategies for individual patients. However, conventional MDT face limitations related to logistics, consensus-building, and patient communication. This review aims to discuss the current status and challenges of MDT in liver cancer management and explore emerging innovative technologies that can transcend the conventional model.
Keywords: hepatocellular carcinoma, multidisciplinary tumor board, precision medicine